ACUMEN PHARMACEUTICALS ($ABOS) posted quarterly earnings results for Q4 2025 on Thursday, March 26th. The company reported earnings of -$0.41 per share, beating estimates of -$0.46 by $0.05. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $ABOS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ACUMEN PHARMACEUTICALS Insider Trading Activity
ACUMEN PHARMACEUTICALS insiders have traded $ABOS stock on the open market 44 times in the past 6 months. Of those trades, 0 have been purchases and 44 have been sales.
Here’s a breakdown of recent trading of $ABOS stock by insiders over the last 6 months:
- DEREK M MEISNER (Chief Legal Officer & Corp Sec) has made 0 purchases and 16 sales selling 115,513 shares for an estimated $248,888.
- DANIEL JOSEPH OCONNELL (Chief Executive Officer) has made 0 purchases and 8 sales selling 86,013 shares for an estimated $163,123.
- MATT ZUGA (CFO & Chief Business Officer) has made 0 purchases and 7 sales selling 25,953 shares for an estimated $49,555.
- RUSSELL BARTON (Chief Operating Officer) has made 0 purchases and 6 sales selling 15,625 shares for an estimated $29,917.
- ERIC SIEMERS (Chief Medical Officer) has made 0 purchases and 4 sales selling 14,060 shares for an estimated $27,110.
- JAMES J. DOHERTY (President and CDO) has made 0 purchases and 2 sales selling 8,167 shares for an estimated $15,148.
- AMY SCHACTERLE (Chief Regulatory Officer) sold 1,097 shares for an estimated $2,176
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ACUMEN PHARMACEUTICALS Hedge Fund Activity
We have seen 25 institutional investors add shares of ACUMEN PHARMACEUTICALS stock to their portfolio, and 43 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- Y-INTERCEPT (HONG KONG) LTD removed 250,848 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $428,950
- GOLDMAN SACHS GROUP INC removed 187,535 shares (-56.0%) from their portfolio in Q3 2025, for an estimated $320,684
- RENAISSANCE TECHNOLOGIES LLC removed 161,192 shares (-27.6%) from their portfolio in Q4 2025, for an estimated $340,115
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 158,758 shares (+74.0%) to their portfolio in Q4 2025, for an estimated $334,979
- CITADEL ADVISORS LLC removed 148,825 shares (-30.1%) from their portfolio in Q4 2025, for an estimated $314,020
- ACADIAN ASSET MANAGEMENT LLC added 74,860 shares (+96.1%) to their portfolio in Q4 2025, for an estimated $157,954
- JANE STREET GROUP, LLC removed 65,116 shares (-31.4%) from their portfolio in Q4 2025, for an estimated $137,394
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ACUMEN PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ABOS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 11/18/2025
To track analyst ratings and price targets for ACUMEN PHARMACEUTICALS, check out Quiver Quantitative's $ABOS forecast page.
ACUMEN PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ABOS recently. We have seen 2 analysts offer price targets for $ABOS in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Thomas Shrader from BTIG set a target price of $8.0 on 03/16/2026
- Geoff Meacham from B of A Securities set a target price of $8.0 on 11/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
